The acquisition, pending regulatory approvals and standard closing formalities, will be finalized for a total amount of JPY 21.5 billion, around ₹1,300 crore. The company indicated that the transaction will be financed through a combination of debt and equity.
MBJ specializes in the research, development, and manufacturing of APIs, intermediates, and offers contract development and manufacturing (CDMO) services. The company possesses expertise in microbial fermentation and biotechnology-based manufacturing, working in areas such as oncology APIs, plasmid DNA manufacturing, ADC conjugation, and enzyme-based bioconversion platforms.
Also Read: Gujarat Themis shares surge 10% on €158 million Sanofi anti-TB portfolio transaction
GTBL noted that this acquisition aligns with its strategy to transition from a fermentation-focused intermediates business to a technology-driven CDMO platform, enhancing its capabilities in precision fermentation, biotechnology, and next-generation drug manufacturing.
The transaction is subject to approvals under Japan’s Foreign Exchange and Foreign Trade Act (FEFTA) and other regulatory requirements. The company anticipates the acquisition will close in Q2 FY27, contingent upon fulfilling standard closing conditions.
MBJ reported projected revenue of JPY 9.5 billion, roughly ₹570 crore, for FY26. Over the past three years, the company’s operational revenue was approximately ₹470 crore in FY23, ₹580 crore in FY24, and ₹560 crore in FY25.
Also Read: Aurobindo Pharma’s Rajasthan facility receives 7 observations from US FDA
GTBL clarified that the acquisition is not classified as a related party transaction and that neither the promoter nor the promoter group has any interest in the entity being purchased.
Shares of Gujarat Themis Biosyn Ltd closed at ₹364.50, marking an increase of ₹7.40, or 2.07%, on the BSE.
(Edited by : Jomy Jos Pullokaran)
